Third Inhaler Company Caps Prices at $35 a Month After Baldwin's Investigation into High Costs
March 21, 2024
March 21, 2024
WASHINGTON, March 21 -- Sen. Tammy Baldwin, D-Wisconsin, issued the following news release:
U.S. Senator Tammy Baldwin (D-WI) applauds GlaxoSmithKline's (GSK) announcement that Americans throughout the country with asthma and COPD will pay no more than $35 for the brand name inhalers they manufacture. With this announcement, GSK joins AstraZeneca and Boehringer Ingelheim as the third major inhaler manufacturer to cap the out-of-pocket costs for their inhaler products at $35 per mont . . .
U.S. Senator Tammy Baldwin (D-WI) applauds GlaxoSmithKline's (GSK) announcement that Americans throughout the country with asthma and COPD will pay no more than $35 for the brand name inhalers they manufacture. With this announcement, GSK joins AstraZeneca and Boehringer Ingelheim as the third major inhaler manufacturer to cap the out-of-pocket costs for their inhaler products at $35 per mont . . .